|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
ES2017924B3
(es)
|
1985-10-11 |
1991-03-16 |
Duphar Int Res B V |
Inyector automatico.
|
|
GB2209937B
(en)
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
|
US5981485A
(en)
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
HU221294B1
(en)
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5578442A
(en)
|
1992-03-23 |
1996-11-26 |
Vivorx, Inc. |
Graft copolymers of polycationic species and water-soluble polymers, and use therefor
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US5643605A
(en)
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5858964A
(en)
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IT1276690B1
(it)
|
1995-06-09 |
1997-11-03 |
Ira Srl |
Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema
|
|
AP665A
(en)
|
1996-01-24 |
1998-08-19 |
United States Governmnet Represented By The Secretary Of The Army |
Novel "burst free" sustained release poly-(lactide/glycolide microspheres).
|
|
WO1997029131A1
(en)
|
1996-02-09 |
1997-08-14 |
Basf Aktiengesellschaft |
HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
|
|
US5792477A
(en)
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
|
US20070185032A1
(en)
|
1996-12-11 |
2007-08-09 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US5945126A
(en)
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
|
AR012448A1
(es)
|
1997-04-18 |
2000-10-18 |
Ipsen Pharma Biotech |
Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
|
|
US6454746B1
(en)
|
1997-06-04 |
2002-09-24 |
Eli Lilly And Company |
Medication delivery apparatus
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
EP1054880A1
(en)
|
1998-02-13 |
2000-11-29 |
Autoimmune, Inc. |
TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
|
|
CA2337688C
(en)
|
1998-07-23 |
2016-04-05 |
Yeda Research And Development Co., Ltd. |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
AU766498B2
(en)
|
1998-07-23 |
2003-10-16 |
President And Fellows Of Harvard College, The |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
EP2239269B1
(en)
|
1998-09-25 |
2013-01-16 |
Yeda Research And Development Co., Ltd. |
Use of peptides derived from copolymer-1 as molecular weight markers
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
AU775073C
(en)
|
1998-11-12 |
2007-05-03 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
|
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
|
US6872739B1
(en)
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
US6531130B1
(en)
|
1999-07-06 |
2003-03-11 |
The Board Of Trustees Of The Leland Stanford University |
Treatment of demyelinating autoimmune disease with ordered peptides
|
|
ATE302020T1
(de)
|
2000-01-20 |
2005-09-15 |
Yeda Res & Dev |
Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
|
|
AU2001238469C1
(en)
|
2000-02-18 |
2006-08-24 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
HUP0302333A3
(en)
|
2000-06-05 |
2005-07-28 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
|
|
CN100438906C
(zh)
|
2000-06-07 |
2008-12-03 |
耶达研究及发展有限公司 |
共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
KR100392501B1
(ko)
|
2000-06-28 |
2003-07-22 |
동국제약 주식회사 |
다중 에멀젼법에 의한 서방출성 미립구의 제조방법
|
|
US8658627B2
(en)
|
2001-04-25 |
2014-02-25 |
The Regents Of The University Of California |
Pregnancy hormone combination for treatment of autoimmune diseases
|
|
US6835711B2
(en)
|
2001-06-28 |
2004-12-28 |
Yeda Research And Development Co. Ltd. |
Use of poly-Glu,Tyr for neuroprotective therapy
|
|
JP4426286B2
(ja)
|
2001-07-10 |
2010-03-03 |
テバ ファーマシューティカル インダストリーズ リミティド |
0次、0次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
|
|
DE02800437T1
(de)
|
2001-10-03 |
2004-11-11 |
The President And Fellows Of Harvard College, Cambridge |
Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren
|
|
ATE511840T1
(de)
|
2001-10-09 |
2011-06-15 |
Amgen Inc |
Imidazolderivate als entzündungshemmende mittel
|
|
AU2002365649A1
(en)
|
2001-11-28 |
2003-06-17 |
Immunomedics, Inc. |
Anti-dota antibody
|
|
JP4369234B2
(ja)
|
2001-12-04 |
2009-11-18 |
テバ ファーマシューティカル インダストリーズ リミティド |
グラチラマー・アセテートの強度の測定のための方法
|
|
DK1429800T3
(da)
|
2001-12-06 |
2009-04-27 |
Yeda Res & Dev |
Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
|
|
US8871241B2
(en)
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
|
CN1398584A
(zh)
|
2002-07-15 |
2003-02-26 |
裴福兴 |
一种bFGF-PLGA缓释微球及其制备方法和用途
|
|
DE10237146A1
(de)
|
2002-08-13 |
2004-03-04 |
Medac Gesellschaft für klinische Spezialpräparate mbH |
Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
|
|
US7199119B2
(en)
|
2002-10-31 |
2007-04-03 |
Amgen Inc. |
Antiinflammation agents
|
|
WO2004043995A2
(en)
|
2002-11-13 |
2004-05-27 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
EP1572271A1
(de)
|
2002-11-25 |
2005-09-14 |
Tecpharma Licensing AG |
Autoinjektor mit rückstellbarer auslösesicherung
|
|
EP1583506B1
(en)
|
2003-01-07 |
2012-03-07 |
Yeda Research And Development Co., Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
ZA200505733B
(en)
|
2003-01-21 |
2006-10-25 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
US20070037740A1
(en)
|
2003-03-04 |
2007-02-15 |
Irit Pinchasi |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PT1638589E
(pt)
|
2003-05-14 |
2014-06-12 |
Teva Pharma |
Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla
|
|
US20050142205A1
(en)
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
|
EP1646445A4
(en)
|
2003-07-18 |
2007-09-19 |
Baxter Int |
METHOD OF MANUFACTURING, USING AND COMPOSING SMALL BALLULAR PARTICLES PRODUCED BY CONTROLLED PHASE SEPARATION
|
|
US20060276390A1
(en)
|
2003-07-31 |
2006-12-07 |
Yeda Research And Development Co. Ltd. |
Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
|
|
WO2005041933A1
(en)
|
2003-10-31 |
2005-05-12 |
Teva Pharmaceutical Industries, Ltd. |
Nanoparticles for drug delivery
|
|
JP5456235B2
(ja)
|
2003-11-12 |
2014-03-26 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
神経変性疾患を治療するためのワクチン及び方法
|
|
AU2005206143B2
(en)
|
2004-01-12 |
2010-12-16 |
The Trustees Of The University Of Pennsylvania |
Long-term delivery formulations and methods of use thereof
|
|
RU2006134701A
(ru)
|
2004-03-01 |
2008-04-10 |
Пептиммьюн |
Способы и композиции для лечения аутоиммунных заболеваний
|
|
WO2005084377A2
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US7576051B2
(en)
|
2004-03-11 |
2009-08-18 |
Sanyo Chemical Industries, Ltd. |
Wound dressing for accelerating epidermal regeneration
|
|
WO2005092066A2
(en)
|
2004-03-25 |
2005-10-06 |
Janssen Pharmaceutica N.V. |
Imidazole compounds
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
RU2410115C2
(ru)
|
2004-05-07 |
2011-01-27 |
Пептиммьюн, Инк. |
Способы лечения заболеваний с помощью статистических сополимеров
|
|
CN106075435A
(zh)
|
2004-06-04 |
2016-11-09 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
|
CA2575604A1
(en)
|
2004-07-30 |
2006-02-02 |
Oregon Health And Science University |
Methods for detecting and treating autoimmune disorders
|
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
EP1796710A4
(en)
|
2004-09-02 |
2010-05-26 |
Teva Pharma |
THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
ES2451006T3
(es)
|
2004-09-09 |
2014-03-26 |
Teva Pharmaceutical Industries Ltd. |
Procedimiento para la preparación de mezclas de acetato de trifluoroacetilglatirámero usando ácido bromhídrico purificado
|
|
JP5297653B2
(ja)
|
2004-10-29 |
2013-09-25 |
サンド・アクチエンゲゼルシヤフト |
グラチラマーの製造法
|
|
CN103169965A
(zh)
|
2004-11-19 |
2013-06-26 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
|
AU2005308396B2
(en)
|
2004-11-29 |
2011-06-09 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
|
|
AU2006211101A1
(en)
|
2005-02-02 |
2006-08-10 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
|
|
AU2006211510B8
(en)
|
2005-02-02 |
2011-04-21 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
US20080279819A1
(en)
|
2005-02-15 |
2008-11-13 |
Adamas Pharmaceuticals, Inc. |
Combinations Therapy for Treatment of Demyelinating Conditions
|
|
WO2006089164A1
(en)
|
2005-02-17 |
2006-08-24 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
EP1891233A4
(en)
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
|
JP2008545660A
(ja)
|
2005-05-20 |
2008-12-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
|
|
WO2007021970A2
(en)
|
2005-08-15 |
2007-02-22 |
Praecis Pharmaceuticals, Inc. |
Stable pharmaceutical formulations and methods of use thereof
|
|
US20070059798A1
(en)
|
2005-09-09 |
2007-03-15 |
Alexander Gad |
Polypeptides useful for molecular weight determinations
|
|
US7517856B2
(en)
|
2005-10-11 |
2009-04-14 |
Ben-Gurion University Of The Negev Research And Development Authority |
Bioconjugates comprising sulfated polysaccharides and their uses
|
|
WO2007081975A2
(en)
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US8410115B2
(en)
|
2006-02-28 |
2013-04-02 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
EP4276469A3
(en)
|
2006-02-28 |
2024-01-17 |
Biogen MA Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
DK2002258T3
(en)
|
2006-03-15 |
2018-01-02 |
Brigham & Womens Hospital Inc |
APPLICATION OF GELSOLINE TO TREAT MULTIPLE SCLEROSIS AND DIAGNOSTICATION OF NEUROLOGICAL DISEASES
|
|
CN101479607B
(zh)
|
2006-04-28 |
2013-10-02 |
莫门塔制药股份有限公司 |
评估肽混合物的方法
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
AU2007264682B2
(en)
|
2006-06-28 |
2012-09-06 |
Yeda Research & Development Co. Ltd |
Method of treatment of age-related macular degeneration
|
|
TWI527603B
(zh)
|
2006-06-30 |
2016-04-01 |
艾伯維生物技術有限責任公司 |
自動注射裝置
|
|
ATE452140T1
(de)
|
2006-07-05 |
2010-01-15 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
|
EP2068845A2
(en)
|
2006-10-06 |
2009-06-17 |
Baxter International Inc. |
Microencapsules containing surface-modified microparticles and methods of forming and using the same
|
|
SG177221A1
(en)
|
2006-12-15 |
2012-01-30 |
Abbott Lab |
Novel oxadiazole compounds
|
|
WO2008075365A1
(en)
|
2006-12-20 |
2008-06-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods for treatment of age related degeneration of the retina
|
|
HUE032251T2
(en)
|
2007-02-08 |
2017-09-28 |
Biogen Ma Inc |
Neuroprotection in demyelinating diseases
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
PT2187882E
(pt)
|
2007-07-11 |
2013-04-17 |
Medicinova Inc |
Tratamento de uma doença neurodegenerativa progressiva com ibudilast
|
|
WO2009040814A1
(en)
|
2007-09-24 |
2009-04-02 |
Hadasit Medical Research Services & Development Ltd |
Use of copolymer 1 for treatment of muscular dystrophy
|
|
KR20100087291A
(ko)
|
2007-09-25 |
2010-08-04 |
아보트 러보러터리즈 |
케모카인 수용체 길항제로서의 옥타하이드로펜탈렌 화합물
|
|
NZ584356A
(en)
|
2007-09-26 |
2011-10-28 |
Univ Oregon Health & Science |
Cyclic undecapeptides and derivatives as multiple sclerosis therapies
|
|
WO2009063459A2
(en)
|
2007-11-13 |
2009-05-22 |
Yeda Research And Development Co. Ltd |
Synthetic peptide copolymers for treatment of neurodevelopmental disorders
|
|
CN101877963A
(zh)
|
2007-11-28 |
2010-11-03 |
泰华制药工业有限公司 |
延缓临床确诊的多发性硬化症发作的方法
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
CA2732228A1
(en)
|
2008-07-25 |
2010-01-28 |
The Johns Hopkins University |
Methods and compositions for treating and preventing autoimmune diseases
|
|
WO2010024908A1
(en)
|
2008-08-26 |
2010-03-04 |
Fibrogen, Inc. |
Methods for treatment of multiple sclerosis
|
|
AU2009291781A1
(en)
|
2008-09-10 |
2010-03-18 |
Acorda Therapeutics, Inc. |
Methods of using sustained release aminopyridine compositions
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
EP2355660A4
(en)
|
2008-10-13 |
2012-05-02 |
Biovista Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
|
|
CN102395275A
(zh)
|
2008-12-11 |
2012-03-28 |
拜欧维斯塔公司 |
用四环吡嗪并吲哚治疗多发性硬化症的方法
|
|
WO2010096558A1
(en)
|
2009-02-18 |
2010-08-26 |
Eyeon Particle Sciences Llc |
Bi-functional co-polymer use for ophthalmic and other topical and local applications
|
|
EP2246048A1
(en)
|
2009-04-30 |
2010-11-03 |
Santhera Pharmaceuticals (Schweiz) AG |
Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
|
|
NZ577731A
(en)
|
2009-06-16 |
2010-08-27 |
Innate Therapeutics Ltd |
Compositions and methods for treatment of multiple sclerosis
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PL2275086T3
(pl)
|
2009-07-15 |
2012-09-28 |
Teva Pharma |
Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania
|
|
JP6038653B2
(ja)
|
2009-08-20 |
2016-12-07 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッドYeda Research And Development Company Limited |
低頻度酢酸グラチラマー治療
|
|
AU2013203367C1
(en)
|
2009-08-20 |
2018-01-18 |
Yeda Research & Development Co., Ltd |
Low frequency glatiramer acetate therapy
|
|
NO2490685T3
(enExample)
|
2009-10-22 |
2018-05-12 |
|
|
|
TR201818858T4
(tr)
|
2010-01-04 |
2019-01-21 |
Mapi Pharma Ltd |
Glati̇ramer asetat i̇çeren depo si̇stemi̇.
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US8828668B2
(en)
|
2010-02-11 |
2014-09-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers for determination of patient responsiveness
|
|
HRP20151350T1
(hr)
|
2010-02-12 |
2016-01-01 |
Biogen Ma Inc. |
Neuroprotekcija kod demijelinizacijskih bolesti
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
EP2598889A4
(en)
|
2010-07-29 |
2014-01-22 |
Reddys Lab Ltd Dr |
MOLECULAR WEIGHT MARKER FOR GLATIRAMERACETATE
|
|
BR112013003823A2
(pt)
|
2010-08-20 |
2016-06-28 |
Cerulean Pharma Inc |
conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados
|
|
WO2012051106A1
(en)
|
2010-10-11 |
2012-04-19 |
Teva Pharmaceutical Industries Ltd. |
Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
|
|
GB2485169A
(en)
|
2010-11-03 |
2012-05-09 |
Univ Jw Goethe Frankfurt Main |
(R)-flurbiprofen for use in the treatment of multiple sclerosis
|
|
EP2500072A1
(en)
|
2011-03-15 |
2012-09-19 |
LEK Pharmaceuticals d.d. |
A novel process of residual solvent removal
|
|
CA2832565A1
(en)
|
2011-04-08 |
2012-10-11 |
Biogen Idec Ma Inc. |
Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
EP2699317B1
(en)
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
|
US11340224B2
(en)
|
2011-05-04 |
2022-05-24 |
Cellular Technology Limited |
Whole brain lysate antigen-specific memory B cell and antibody assays in multiple sclerosis
|
|
US20140348861A1
(en)
|
2011-05-05 |
2014-11-27 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
DK2529757T3
(en)
|
2011-05-31 |
2014-02-24 |
Rovi Lab Farmaceut Sa |
Paliperidonimplantatformulering
|
|
MX2014004309A
(es)
|
2011-10-10 |
2015-07-06 |
Teva Pharma |
Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
|
|
RU2014141056A
(ru)
|
2012-03-12 |
2016-05-10 |
МЕДИММЬЮН, ЭлЭлСи |
Лечение рассеянного склероза при помощи антитела к cd19
|
|
GB201208850D0
(en)
|
2012-05-18 |
2012-07-04 |
Alphaptose Gmbh |
Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis
|
|
US9132138B2
(en)
|
2012-08-27 |
2015-09-15 |
Casi Pharmaceuticals, Inc. |
Method for the treatment of multiple sclerosis
|
|
BR112015007780A2
(pt)
|
2012-10-09 |
2017-11-28 |
Biogen Idec Inc |
molécula de anticorpo anti-lingo-1, seu uso para tratamento de distúrbios desmielinantes, kit e composição embalada
|
|
NZ630421A
(en)
|
2012-10-10 |
2018-07-27 |
Teva Pharma |
Biomarkers predictive for clinical response for glatiramer acetate
|
|
CN105228651A
(zh)
|
2013-01-04 |
2016-01-06 |
泰华制药工业有限公司 |
表征醋酸格拉替雷相关的药品
|
|
CN105163730B
(zh)
|
2013-01-08 |
2018-10-30 |
帕萨罗杰卡有限公司 |
用于治疗脱髓鞘疾病的方法和组合物
|
|
HK1218254A1
(zh)
|
2013-02-15 |
2017-02-10 |
Teva Pharmaceutical Industries Ltd. |
用拉喹莫德治疗多发性硬化症
|
|
AU2014248524A1
(en)
|
2013-03-12 |
2015-10-29 |
Teva Pharmaceutical Industries Ltd. |
Rituximab induction therapy followed by glatiramer acetate therapy
|
|
WO2014145203A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
CN103169670B
(zh)
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
|
CA2922805A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd. |
Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
EP3119413B1
(en)
|
2014-03-17 |
2021-05-12 |
Mapi Pharma Limited |
Sublingual delivery of glatiramer acetate
|
|
EP3137087B1
(en)
|
2014-04-28 |
2023-09-06 |
The Regents of the University of California |
Estrogen combination for treatment of multiple sclerosis
|
|
WO2016036719A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Estrogen therapy for brain gray matter atrophy and associated disability
|
|
EP3782616B1
(en)
|
2014-09-02 |
2023-11-01 |
The Regents of The University of California |
Estrogen receptor ligand treatment for neurodegenerative diseases
|
|
WO2016040861A1
(en)
|
2014-09-12 |
2016-03-17 |
Biogen Ma Inc. |
Systems and methods for characterization of multiple sclerosis
|
|
WO2016064997A1
(en)
|
2014-10-22 |
2016-04-28 |
The Regents Of The University Of California |
Compositions and methods for treating fatigue and depression
|
|
EP3242893A1
(en)
|
2015-01-08 |
2017-11-15 |
Biogen MA Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
US20160213633A1
(en)
|
2015-01-28 |
2016-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Method of inducing anti-glatiramer acetate antibody response
|
|
EP3277285B1
(en)
|
2015-03-30 |
2024-07-17 |
The Regents of the University of California |
Estriol for reducing cortical gray matter atrophy
|
|
WO2016160830A1
(en)
|
2015-03-30 |
2016-10-06 |
The Regents Of The University Of California |
Methods of providing neuroprotective therapy
|
|
EP3478300B1
(en)
*
|
2016-06-30 |
2022-08-24 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
MX2019001999A
(es)
|
2016-08-28 |
2019-08-29 |
Mapi Pharma Ltd |
Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
|
|
BR112019017724A2
(pt)
|
2017-03-26 |
2020-03-31 |
Mapi Pharma Ltd. |
Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
|
|
EP3624815A4
(en)
|
2017-05-15 |
2021-01-20 |
Stem Cell Medicine Ltd. |
TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS
|